insulin resistance and glp-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP-1 actions and target organs.

By selectively augmenting insulin release, modulation of GLP-1R trafficking may be a viable strategy to achieve greater metabolic control in T2D without increasing the rate of unwanted side effects, such as nausea

The FDAapproved tesamorelin dose is 2 mg SC daily [3] , while ipamorelin is commonly studied at 100300 mcg SC daily [4]

0.5-1 inch on arms represents excellent results for most users

Aid for those with GSTP1, GSTM1 and GPX Gene mutations

Annu Rev Neurosci 27 : 279306

Supplements may support healthy eating habits and metabolic health, but their effects are generally at best modest and much less predictable across patients. The bottom line I would convey to patients is that tried and true lifestyle interventions adequate protein, fiber, resistance training, sleep, and stress management, remain the most reliable natural tools for appetite regulation, Dr